



FOR IMMEDIATE RELEASE

**Immunotec announces the nomination of Mario Paradis
to its Board of Directors and reports AGM results**

VAUDREUIL-DORION, QC, April 28, 2016 – Immunotec Inc. (TSXV: IMM), a direct-to-consumer company and a leader in the nutritional industry (the “Company” or “Immunotec”), today reported the results of its Annual General Meeting of Shareholders held on April 27, 2016 (“AGM”).

During the AGM, all current directors of the Company were re-elected and Mr. Mario Paradis was newly elected to serve as a director of Immunotec. PricewaterhouseCoopers LLP was reappointed as the Company’s auditor.

Mario Paradis is Vice-President and Chief Financial Officer of Neptune Technologies and Bioressources Inc. and of Acasti Pharma Inc. since 2015. Between 2008 and 2015, Mr. Paradis was Vice-President and Chief Financial Officer at Atrium Innovations Inc., which was acquired in 2014 by corporations backed by the Permira Funds in a transaction valued at over \$1.1 billion. Prior to this, Mr. Paradis held roles of increasingly authority at Aeterna Zentaris, most notably as Vice-President Finance and Administration & Corporate Secretary. Mr. Paradis began his career at PricewaterhouseCoopers (PwC), where he successfully held senior positions primarily in audit and tax. Mr. Paradis is a member of the Canadian Chartered Professional Accountants (CPA). He holds a Bachelor’s degree in Business, with a specialty in Accounting, from Université du Québec at Trois-Rivières.

“We are pleased to welcome Mario”, said Rod Budd, Chairman of the Board of Directors. “His experience in the natural health products industry combined with his background as a seasoned accounting and finance executive will be of great value to our Company.”

On April 27, 2016, the Board of Directors of Immunotec also approved the amendment of the Company’s Stock Option Plan (the “Plan”) to allow the automatic extension, for a period of ten (10) business days, to the expiry date of a stock option governed by the Plan if such expiry date falls within a period during which the Company prohibits optionees from exercising their stock options. Such amendment is subject to the approval of the TSX Venture Exchange.

About Immunotec Inc.

Immunotec is a Canadian-based company that develops, manufactures, markets and sells research-driven nutritional products through direct-to-consumer sales channels in Canada, the U.S., Mexico, the Dominican Republic, the United Kingdom and Ireland. The Company offers an extensive family of nutritional, skin care and wellness products targeting health, weight management, energy and physical performance.

Please visit us at www.immunotec.com for additional information.

The Company files its continuous disclosure documents, inclusive of its year end results, on the SEDAR database at www.sedar.com and on the Company’s website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture

Exchange under the ticker symbol IMM. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information:

Patrick Montpetit, CPA, CA, CF Vice-President and Chief Financial Officer (450) 510-4527.